DrugPatentWatch (@DrugPatentWatch) header
DrugPatentWatch (@DrugPatentWatch) profile picture

DrugPatentWatch

@DrugPatentWatch

Pharmaceutical Business Intelligence: https://teapawt.org/t.co/yN4hlGk3Jv Helping Drug Companies Make Better Decisions

 Washington, DC
DrugPatentWatch.com
Joined May 2009
  • Tweets107K
  • Following462
  • Followers14.2K
42.7KMedia
Photo by DrugPatentWatch (@DrugPatentWatch)Photo by DrugPatentWatch (@DrugPatentWatch)Photo by DrugPatentWatch (@DrugPatentWatch)Photo by DrugPatentWatch (@DrugPatentWatch)Photo by DrugPatentWatch (@DrugPatentWatch)Photo by DrugPatentWatch (@DrugPatentWatch)Photo by DrugPatentWatch (@DrugPatentWatch)Photo by DrugPatentWatch (@DrugPatentWatch)Photo by DrugPatentWatch (@DrugPatentWatch)Photo by DrugPatentWatch (@DrugPatentWatch)
Best Practices for Drug Patent Portfolio Management P.S. If you like this post please 1) Like it (so I know it's useful) and 2) Repost and share it (so others can see it too) drugpatentwatch.com/blog/bes…
Drug Patent Portfolio Management: The Definitive Playbook for Pharma IP Teams

Drug Patent Portfolio Management: The Definitive Playbook for Pharma IP Teams

Pharmaceutical patent portfolio management is not a legal overhead function. It is the mechanism by which an industry that spends an average of $1-2 billion and 10-13 years to bring a single drug to…

drugpatentwatch.com
1
738
The Forum You File In Changes Your Odds More Than the Merits Do drugpatentwatch.com/blog/the…
Image from DrugPatentWatch (@DrugPatentWatch)
69
The Supply Agreement Clause Nobody Negotiates: What Happens When the Patent Gets Invalidated Early drugpatentwatch.com/blog/the…
Image from DrugPatentWatch (@DrugPatentWatch)
53
Cut Drug R&D Costs by 90%: The 505(b)(2) Playbook the Big Pharma Textbook Ignores drugpatentwatch.com/blog/cut…
Image from DrugPatentWatch (@DrugPatentWatch)
75
DrugPatentWatch and Bloomberg: Are there too many generic patent challenges? drugpatentwatch.com/blog/dru…
Image from DrugPatentWatch (@DrugPatentWatch)
77
Drug Naming Now Costs $28,000 a Word: Inside the USAN, INN, and FDA System That Decides What Every Medicine Is Called drugpatentwatch.com/blog/dru…
Image from DrugPatentWatch (@DrugPatentWatch)
74
Before You Call: What a Pharma Strategy Team Must Verify Before Approaching a Drug’s Owner drugpatentwatch.com/blog/bef…
Image from DrugPatentWatch (@DrugPatentWatch)
58
500 Drugs, 5 Years: What to Do With a Patent Expiry List drugpatentwatch.com/blog/500…
Image from DrugPatentWatch (@DrugPatentWatch)
59
Patent Expiration Isn’t Generic Entry: How to Find the Date That Counts drugpatentwatch.com/blog/pat…
Image from DrugPatentWatch (@DrugPatentWatch)
59
Why Your PBM’s Generic Substitution Policy Is Six Months Behind the Actual Patent Timeline drugpatentwatch.com/blog/why…
Image from DrugPatentWatch (@DrugPatentWatch)
87
Patent Expiration to Partnership Target: What 9 Deals Show drugpatentwatch.com/blog/pat…
Image from DrugPatentWatch (@DrugPatentWatch)
57
The API Shipment Data Already Told You Who’s Entering the Market — Nobody on Your Team Is Reading It drugpatentwatch.com/blog/the…
Image from DrugPatentWatch (@DrugPatentWatch)
56
A Patent Expiry Date Is Not a Pharma Partnership Plan drugpatentwatch.com/blog/a-p…
Image from DrugPatentWatch (@DrugPatentWatch)
65
Drug Patent Portfolios More Than Tripled Since 1990. Here Is What Changed drugpatentwatch.com/blog/dru…
Image from DrugPatentWatch (@DrugPatentWatch)
39
The Territoriality Trap: Why a US Patent Win Means Nothing Where the Molecule Was Never Filed drugpatentwatch.com/blog/the…
Image from DrugPatentWatch (@DrugPatentWatch)
1
90
Ro vs. Hims & Hers: What the Compounding Crackdown Actually Did drugpatentwatch.com/blog/ro-…
Image from DrugPatentWatch (@DrugPatentWatch)
74
Authorized Generics vs. Your Forecast: The No-AG Assumption Fails 43% of the Time drugpatentwatch.com/blog/aut…
Image from DrugPatentWatch (@DrugPatentWatch)
88
The State Drug Affordability Board Is Watching Patent Listings You Haven’t Checked in a Year drugpatentwatch.com/blog/the…
Image from DrugPatentWatch (@DrugPatentWatch)
64
More Patents, Less Signal: Why a Bigger Drug Patent Database Can Give You Worse Intelligence drugpatentwatch.com/blog/mor…
Image from DrugPatentWatch (@DrugPatentWatch)
73
A ‘Strong Patent Portfolio’ Slide Is a Red Flag: What the Evidence Shows drugpatentwatch.com/blog/a-s…
Image from DrugPatentWatch (@DrugPatentWatch)
60
Patent Expiration Isn't Generic Entry: How to Find the Date That Counts drugpatentwatch.com/blog/pat…
Image from DrugPatentWatch (@DrugPatentWatch)
88
Load more